Engineering Immune Cells

Human natural killer cell. NIAID, via Wikimedia Commons. Distributed under a CC BY 2.0 license.

In a new proof-of-concept study, researchers from Nationwide Children’s Hospital used CRISPR/Cas9 technology to genetically modify natural killer immune cells, which they then showed are able to address a recognized hurdle in immunotherapy of multiple myeloma.

Read the story at Pediatrics Nationwide: Modifying NK Cells With CRISPR/Cas9.